| Title |
Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
|
|---|---|
| Published in |
Cancer Management and Research, March 2018
|
| DOI | 10.2147/cmar.s133291 |
| Pubmed ID | |
| Authors |
Nathan M Denlinger, Narendranath Epperla, Basem M William |
| Abstract |
Marginal zone lymphomas (MZLs) consist of a diverse family of malignancies, which are derived from B-cells. The disease subtypes are recognized extranodal, nodal, and splenic MZLs. The disease characteristics, clinical course, and treatment vary considerably based on the site of involvement. In 2017, the US Food and Drug Administration approved ibrutinib, a first in class Bruton's tyrosine kinase inhibitor that revolutionized the care of chronic lymphocytic leukemia patients; for, the treatment of relapsed/refractory MZL based on pivotal open-label Phase II trial demonstrated an overall response rate of 48%, with a complete response rate of 3%, median progression-free survival of 14.2 months, and median overall survival not yet reached at a median follow-up of 19.4 months. In this review, we aim to summarize the current conundrums in the management of MZL and the evolving role of ibrutinib in the treatment of MZL. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 43 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 8 | 19% |
| Researcher | 6 | 14% |
| Student > Master | 4 | 9% |
| Student > Bachelor | 3 | 7% |
| Student > Ph. D. Student | 2 | 5% |
| Other | 6 | 14% |
| Unknown | 14 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 40% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
| Biochemistry, Genetics and Molecular Biology | 3 | 7% |
| Business, Management and Accounting | 1 | 2% |
| Chemical Engineering | 1 | 2% |
| Other | 4 | 9% |
| Unknown | 14 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 62. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 February 2020.
All research outputs
#587,101
of 23,047,237 outputs
Outputs from Cancer Management and Research
#12
of 2,017 outputs
Outputs of similar age
#15,035
of 331,175 outputs
Outputs of similar age from Cancer Management and Research
#2
of 40 outputs
Altmetric has tracked 23,047,237 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,017 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,175 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.